Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.

Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, Galán I, Río J, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez B, Midaglia L, Mulero P, Mitjana R, Auger C, Sastre-Garriga J, Montalban X, Tintoré M.

Neurology. 2019 Mar 26;92(13):e1507-e1516. doi: 10.1212/WNL.0000000000007178. Epub 2019 Mar 1.

2.

Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.

Pappolla A, Midaglia L, Boix Rodríguez CP, Puig AA, Lung M, Camps IR, Castilló J, Mulero P, Vidal-Jordana A, Arrambide G, Rodriguez-Acevedo B, Sastre-Garriga J, Río J, Comabella M, Galán I, Tintoré M, Montalbán X.

Neurology. 2019 Feb 5;92(6):296-298. doi: 10.1212/WNL.0000000000006801. Epub 2018 Dec 26. No abstract available.

PMID:
30587519
3.

Treatment of multiple sclerosis - success from bench to bedside.

Tintore M, Vidal-Jordana A, Sastre-Garriga J.

Nat Rev Neurol. 2019 Jan;15(1):53-58. doi: 10.1038/s41582-018-0082-z. Review.

PMID:
30315270
4.

Multiple sclerosis: clinical aspects.

Oh J, Vidal-Jordana A, Montalban X.

Curr Opin Neurol. 2018 Dec;31(6):752-759. doi: 10.1097/WCO.0000000000000622. Review.

PMID:
30300239
5.

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course.

Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M.

J Neuroinflammation. 2018 Sep 14;15(1):265. doi: 10.1186/s12974-018-1307-1.

6.

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X.

Brain. 2018 Apr 1;141(4):1075-1084. doi: 10.1093/brain/awy006.

PMID:
29462277
7.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
8.

New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis.

Vidal-Jordana A.

Neurol Clin. 2018 Feb;36(1):173-183. doi: 10.1016/j.ncl.2017.08.011. Review.

PMID:
29157398
9.

Characteristics of morphologic macular abnormalities in neuroimmunology practice.

Al-Louzi O, Sotirchos ES, Vidal-Jordana A, Beh SC, Button J, Ying HS, Balcer LJ, Frohman EM, Saidha S, Calabresi PA, Newsome SD.

Mult Scler. 2019 Mar;25(3):361-371. doi: 10.1177/1352458517741206. Epub 2017 Nov 10.

PMID:
29125422
10.

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X.

Neurology. 2017 Dec 5;89(23):2351-2356. doi: 10.1212/WNL.0000000000004715. Epub 2017 Nov 3.

11.

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2018 May;24(6):721-727. doi: 10.1177/1352458517707070. Epub 2017 Apr 26.

PMID:
28445084
12.

Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.

Vidal-Jordana A, Montalban X.

Neuroimaging Clin N Am. 2017 May;27(2):195-204. doi: 10.1016/j.nic.2016.12.001. Review.

PMID:
28391781
13.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M.

Mult Scler. 2018 Mar;24(3):301-312. doi: 10.1177/1352458517697830. Epub 2017 Mar 16.

PMID:
28301287
14.

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X.

Mult Scler. 2018 Mar;24(3):322-330. doi: 10.1177/1352458517698052. Epub 2017 Mar 13.

PMID:
28287331
15.

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

Matute-Blanch C, Río J, Villar LM, Midaglia L, Malhotra S, Álvarez-Cermeño JC, Vidal-Jordana A, Montalban X, Comabella M.

J Neuroimmunol. 2017 Feb 15;303:62-65. doi: 10.1016/j.jneuroim.2016.12.006. Epub 2016 Dec 18.

PMID:
28063616
16.

Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images.

Vidal-Jordana A, Pareto D, Sastre-Garriga J, Auger C, Ciampi E, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2017 Feb;38(2):250-256. doi: 10.3174/ajnr.A4999. Epub 2016 Nov 24.

17.

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X.

Neurology. 2016 Sep 27;87(13):1368-74. doi: 10.1212/WNL.0000000000003144. Epub 2016 Aug 26.

PMID:
27566747
18.

Neurofilament light chain level is a weak risk factor for the development of MS.

Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M.

Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Epub 2016 Aug 12. Erratum in: Neurology. 2016 Nov 8;87(19):2068.

19.

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

Ciampi E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, Tur C, Río J, Tintoré M, Auger C, Rovira A, Montalban X.

Mult Scler. 2017 Apr;23(4):556-566. doi: 10.1177/1352458516656808. Epub 2016 Jul 11.

PMID:
27354019
20.

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.

Midaglia L, Juega Mariño JM, Sastre-Garriga J, Rovira A, Vidal-Jordana A, López-Pérez MA, Marzo-Sola ME, Librada Escribano F, Montalban X.

Mult Scler. 2016 May;22(6):842-6. doi: 10.1177/1352458516638557. Epub 2016 Mar 18.

PMID:
26993120
21.

Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.

Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X.

J Neuroimaging. 2016 Sep;26(5):532-8. doi: 10.1111/jon.12337. Epub 2016 Mar 2.

PMID:
26935253
22.

Predictive value of early brain atrophy on response in patients treated with interferon β.

Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 2;2(4):e132. doi: 10.1212/NXI.0000000000000132. eCollection 2015 Aug.

23.

Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X.

J Neurol. 2015 Dec;262(12):2617-26. doi: 10.1007/s00415-015-7798-0. Epub 2015 Jun 5. Review.

PMID:
26041617
24.

Defining high, medium and low impact prognostic factors for developing multiple sclerosis.

Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X.

Brain. 2015 Jul;138(Pt 7):1863-74. doi: 10.1093/brain/awv105. Epub 2015 Apr 21.

PMID:
25902415
25.

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis.

Malhotra S, Fissolo N, Tintoré M, Wing AC, Castilló J, Vidal-Jordana A, Montalban X, Comabella M.

J Neuroinflammation. 2015 Mar 11;12:48. doi: 10.1186/s12974-015-0269-9.

26.

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

Negrotto L, Tur C, Tintoré M, Arrambide G, Sastre-Garriga J, Río J, Comabella M, Nos C, Galán I, Vidal-Jordana A, Simon E, Castilló J, Palavra F, Mitjana R, Auger C, Rovira À, Montalban X.

Mult Scler. 2015 Dec;21(14):1802-10. doi: 10.1177/1352458515575338. Epub 2015 Mar 16.

PMID:
25778697
27.

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, Villar LM, Alvarez-Cermeño JC, Izquierdo G, Fernández O, Oliver B, Saiz A, Ara JR, Vigo AG, Arroyo R, Meca V, Malhotra S, Fissolo N, Horga A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047. eCollection 2014 Dec.

28.

Brain atrophy in natalizumab-treated patients: A 3-year follow-up.

Sastre-Garriga J, Tur C, Pareto D, Vidal-Jordana A, Auger C, Río J, Huerga E, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2015 May;21(6):749-56. doi: 10.1177/1352458514556300. Epub 2014 Nov 12.

PMID:
25392330
29.

Significant clinical worsening after natalizumab withdrawal: Predictive factors.

Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, Nos C, Arrambide G, Comabella M, Galán I, Castilló J, Sastre-Garriga J, Rovira A, Montalban X.

Mult Scler. 2015 May;21(6):780-5. doi: 10.1177/1352458514549401. Epub 2014 Nov 12.

PMID:
25392320
30.

Biomarkers in multiple sclerosis: an update for 2014.

Fernandez O, Martin R, Rovira A, Llufriu S, Vidal-Jordana A, Fernandez-Sanchez VE, Alvarez-Cermeno JC, Izquierdo G, Arroyo-Gonzalez R, Rodriguez-Antiguedad A, Casanova-Estruch B, Montalban X.

Rev Neurol. 2014 Jun 16;58(12):553-70. Review. English, Spanish.

31.

Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis.

Fissolo N, Cantó E, Vidal-Jordana A, Castilló J, Montalban X, Comabella M.

J Neuroimmunol. 2014 Jun 15;271(1-2):56-9. doi: 10.1016/j.jneuroim.2014.04.001. Epub 2014 Apr 16.

PMID:
24794503
32.

Activation-induced cell death in T lymphocytes from multiple sclerosis patients.

Moreno M, Negrotto L, Río J, Moubarak R, Martín I, Bustamante MF, Comella JX, Vidal-Jordana A, Pérez-Boza J, Montalban X, Comabella M.

J Neuroimmunol. 2014 Jul 15;272(1-2):51-5. doi: 10.1016/j.jneuroim.2014.04.007. Epub 2014 Apr 16.

33.

Radiologically isolated syndrome: 5-year risk for an initial clinical event.

Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le H, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP).

PLoS One. 2014 Mar 5;9(3):e90509. doi: 10.1371/journal.pone.0090509. eCollection 2014.

34.

Comment on 'isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis' by Stefan Kipfer and David W Crook.

Vidal-Jordana A.

Mult Scler. 2014 May;20(6):756. doi: 10.1177/1352458513518628. Epub 2014 Jan 9. No abstract available.

PMID:
24407770
35.

Comment on: 'Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients'.

Vidal-Jordana A, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2014 Jun;20(7):897-8. doi: 10.1177/1352458513515959. Epub 2013 Dec 18. No abstract available.

PMID:
24351437
36.

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

Tur C, Tintoré M, Vidal-Jordana Á, Bichuetti D, Nieto González P, Arévalo MJ, Arrambide G, Anglada E, Galán I, Castilló J, Nos C, Río J, Martín MI, Comabella M, Sastre-Garriga J, Montalban X.

PLoS One. 2013 Dec 10;8(12):e82796. doi: 10.1371/journal.pone.0082796. eCollection 2013.

37.

Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis.

Moreno M, Sáenz-Cuesta M, Castilló J, Cantó E, Negrotto L, Vidal-Jordana A, Montalban X, Comabella M.

J Neuroimmunol. 2013 Oct 15;263(1-2):152-4. doi: 10.1016/j.jneuroim.2013.07.013. Epub 2013 Jul 26.

PMID:
23932896
38.

TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients.

Malhotra S, Castilló J, Negrotto L, Merino-Zamorano C, Montaner J, Vidal-Jordana A, Montalban X, Comabella M.

J Neuroimmunol. 2013 Aug 15;261(1-2):146-8. doi: 10.1016/j.jneuroim.2013.05.013. Epub 2013 Jun 22.

PMID:
23796873
39.

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, Horga A, Auger C, Río J, Nos C, Edo MC, Arévalo MJ, Castilló J, Rovira A, Montalban X.

Mult Scler. 2013 Aug;19(9):1175-81. doi: 10.1177/1352458512473190. Epub 2013 Jan 14.

PMID:
23319072
40.

SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.

Malhotra S, Castilló J, Bustamante M, Vidal-Jordana A, Castro Z, Montalban X, Comabella M.

Mult Scler. 2013 Apr;19(5):524-31. doi: 10.1177/1352458512458718. Epub 2012 Aug 29.

PMID:
22933622
41.

Value of NMO-IgG determination at the time of presentation as CIS.

Costa C, Arrambide G, Tintore M, Castilló J, Sastre-Garriga J, Tur C, Río J, Saiz A, Vidal-Jordana A, Auger C, Nos C, Rovira A, Comabella M, Horga A, Montalban X.

Neurology. 2012 May 15;78(20):1608-11. doi: 10.1212/WNL.0b013e3182563b32. Epub 2012 May 2.

PMID:
22551725
42.

[Optical coherence tomography in multiple sclerosis].

Vidal-Jordana Á, Sastre-Garriga J, Montalban X.

Rev Neurol. 2012 May 1;54(9):556-63. Review. Spanish.

43.

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.

Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.

Mult Scler. 2012 Aug;18(8):1193-6. doi: 10.1177/1352458512439238. Epub 2012 Mar 1.

PMID:
22383232
44.

[Headache and immigration. A study in the outpatient department of the Hospital de la Santa Creu i Sant Pau in Barcelona].

Vidal-Jordana A, Barroeta-Espar I, Sainz-Pelayo MP, Sala I, Roig C.

Rev Neurol. 2011 Sep 1;53(5):275-80. Spanish.

45.

Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.

Martinez-Ramirez S, Delgado-Mederos R, Marín R, Suárez-Calvet M, Sáinz MP, Alejaldre A, Vidal-Jordana Á, Martí-Vilalta JL, Martí-Fàbregas J.

J Neurol. 2012 Jan;259(1):111-8. doi: 10.1007/s00415-011-6137-3. Epub 2011 Jun 18.

PMID:
21688044
46.

[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].

Vidal-Jordana A, Barroeta-Espar I, Sáinz Pelayo MP, Mateo J, Delgado-Mederos R, Martí-Fàbregas J.

Neurologia. 2012 Apr;27(3):136-42. doi: 10.1016/j.nrl.2011.04.020. Epub 2011 Jun 16. Spanish.

Supplemental Content

Loading ...
Support Center